New Perspectives in Experimental and Clinical Research for Cutaneous T Cell Lymphomas

Burg, Günter; Häffner, Andreas C.; Böni, R.; Dommann, Stefan; Dummer, Reinhard

doi:10.1007/978-3-642-78771-3_17

Cited by 8 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The term cutaneous T‐cell lymphoma (CTCL) refers to a group of low‐grade, non‐Hodgkin lymphomas, including Sézary syndrome and mycosis fungoides and its variants 1 . Sézary syndrome, the leukemic and most aggressive subtype of CTCL, carries a poor prognosis 2 .…”

Section: Introductionmentioning

confidence: 99%

Oral bexarotene in a therapy‐resistant Sézary syndrome patient: observations on Sézary cell compartmentalization

el‐Azhary

Bouwhuis

2004

Int J Dermatology

View full text Add to dashboard Cite

Background A 63-year-old man with therapy-resistant Sézary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced-stage cutaneous T-cell lymphoma (CTCL).Methods Monthly evaluations for efficacy and side-effects were conducted and documented.Results Gradual improvement in erythema, pruritus, and scale was noted during the initial 16-week trial period and treatment was extended to 40 weeks. From week 20 to week 40, the erythroderma continued to improve and the lymph node burden decreased, but the absolute Sézary cell count inversely increased. By week 40, intractable pruritus and erythroderma abruptly recurred, and bexarotene was discontinued.Conclusions Bexarotene is well tolerated and can be efficacious in patients with Sézary syndrome. Shifting of Sézary cells between different compartments was noted. Further studies on the interaction between the skin, lymph nodes, and peripheral blood compartments during bexarotene treatment in this subset of patients with CTCL are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral bexarotene in a therapy‐resistant Sézary syndrome patient: observations on Sézary cell compartmentalization

el‐Azhary

Bouwhuis

2004

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…So scheint auch das Th2-Zytokinmuster (IL-4,IL-5,IL-6,IL-10) an der Pathogenese der kutanen T-Zell-Lymphome beteiligt [10,41]. Die Ergebnisse divergieren, jedoch liegen vermehrt Hinweise dafür vor, dass ein Defekt der monozytären IL-12-Produktion und eine defekte Signaltransduktion des IL-12 zugrunde liegen.…”

Section: Kutane T-zell-lymphomeunclassified

Zytokine

Nashan¹,

Luger²

2001

Der Hautarzt

View full text Add to dashboard Cite

Various therapeutic options using cytokines have been described in the treatment of melanoma, T cell lymphoma, B cell lymphoma, squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. The treatment regimens include cytokine substitution, cytokine induction, cytokine transfection and therapeutic cytokine constructs. In the adjuvant treatment of melanomas, IFN-alpha has become well established. Statistical evaluations of different adjuvant trials show that a significant prolongation of recurrence-free intervals can be achieved. IL-2 has a role in the therapy of advanced melanomas as well as in vaccination strategies. Further possible therapeutic immune modulations, which have been evaluated in experimental approaches and pilot studies, include treatment with IL-4, IL-7 and GM-CSF. Treatment with IL-12 promises to open new perspectives. A well established regimen in the treatment of T cell lymphoma stages Ia-IIb is the combination of PUVA and IFN-alpha. In vitro data also indicate an important (patho)physiological role for IL-12, so that this agent has been tested in phase I studies. IL-2, IFN-gamma, and the fused cytokine-toxin molecules DAB389IL-2 offer further therapeutic alternatives. B cell lymphomas are treated with antibody-IL-2 fusion proteins. Advanced or inoperable squamous cell carcinoma and basal cell carcinoma may be treated with local IFN-alpha injections. IFN-alpha or TNF-alpha may be considered for the treatment of recurrent or advanced Merkel cell carcinoma. In dermatological oncology cytokine treatment focuses on melanome an T cell lymphome. Cytokine application is mainly an integral part of multimodal regimens.

show abstract

“…Above that, cytokines are increasingly used in the treatment of lymphoproliferative and other diseases. Cytokines are considered to be of major importance for the pathogenesis of cutaneous T-cell lymphomas (CTCL) (1)(2)(3)(4). Their considerable impact may result from autocrine, paracrine or endocrine effects: -autocrine effects might be responsible for stimulation of the malignant cell proliferation; -paracrine effects may influence the anti-tumor immune response (stimulation or depression); -endocrine effects may be responsible for systemic abnormalities observed in CTCL patients.…”

mentioning

confidence: 99%

Cytokines and cutaneous T‐cell lymphomas

Asadullah

Döcke

Volk

et al. 1998

Experimental Dermatology

View full text Add to dashboard Cite

Cytokines are considered to be of major importance for the University Berlin, Germany pathogenesis of cutaneous T-cell lymphomas (CTCL). Their impact may result from autocrine, paracrine or endocrine effects. Several investigations demonstrated the overexpression of different cytokines in different CTCL entities. Interestingly, stage-dependent shifts in the cytokine pattern have been observed in mycosis fungoides (MF). There is evidence that the abnormal cytokine expression in CTCL might be responsible for tumor progression, resulting from an enhanced proliferation of the malignant cells and/or the depression of the anti-tumor immune response.

show abstract

New Perspectives in Experimental and Clinical Research for Cutaneous T Cell Lymphomas

Cited by 8 publications

References 41 publications

Oral bexarotene in a therapy‐resistant Sézary syndrome patient: observations on Sézary cell compartmentalization

Oral bexarotene in a therapy‐resistant Sézary syndrome patient: observations on Sézary cell compartmentalization

Zytokine

Cytokines and cutaneous T‐cell lymphomas

Contact Info

Product

Resources

About